autosomal dominant polycystic kidney disease
Rare disease · 2017–2018
3decisions
1medicine
3carried consumer input
74individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tolvaptan To slow the progression of cyst development and renal insufficiency in adults with autosomal dominant polycystic kidney disease (ADPKD) with chronic kidney… | Jul 2018 | Recommended with restriction | 17 individuals |
| tolvaptan Autosomal dominant polycystic kidney disease (ADPKD) in patients with chronic kidney disease stages 2–3 at initiation of treatment with evidence of rapidly… | Mar 2018 | Deferred | 49 individuals |
| tolvaptan Treatment of autosomal dominant polycystic kidney disease (ADPKD) in patients with CKD stages 1-3 and evidence of rapid disease progression. | Mar 2017 | Not recommended | 8 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.